Skip to content

Study comparing glutamine supplement to reduce mouth sores in children with blood cancer undergoing chemotherapy

Comparative evaluation of efficacy of Glutamine supplementation in management of oral mucositis before and during chemotherapy in children with Acute Lymphoblastic Leukemia (ALL)- An Invivo study - nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/092036
Enrollment
60
Registered
2025-07-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D728- Other specified disorders of whiteblood cells

Interventions

Intervention1: Oncoglute powder: Oncoglute powder 15g which contains L-Glutamine, Vitamin A, Vitamin C, Vitamin E with selenium will be given daily one sachet for 5 days Control Intervention1: Not app

Sponsors

Siddhartha Medical College , Vijayawada
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age group- 2 to 14 years Children with Acute lymphoblastic leukemia (ALL) Children with ALL before chemotherapy treatment Children with ALL undergoing chemotherapy Children with Oral Mucositis Subject Parent willingness

Exclusion criteria

Exclusion criteria: age group morethan 15 years Children without Acute lymphoblastic leukemia

Design outcomes

Primary

MeasureTime frame
To reduce the severity of oral mucositis in chemotherapy patients with ALLTimepoint: The outcome will be assessed in 3 weeks after the supplementation of glutamine

Secondary

MeasureTime frame
Improves nutritional value & have proper appetiteTimepoint: The nutritional value improvement can be seen after the reduction of mucositis (after 3 weeks )

Countries

India

Contacts

Public ContactP Manasa

Government Dental College and Hospital Vijayawada

jesudass.govada@gmail.com9618810707

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026